These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21431636)

  • 1. Cytogenetics of myeloproliferative neoplasms.
    Campbell LJ
    Methods Mol Biol; 2011; 730():89-98. PubMed ID: 21431636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
    Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
    Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3.
    Tzankov A; Sotlar K; Muhlematter D; Theocharides A; Went P; Jotterand M; Horny HP; Dirnhofer S
    J Clin Pathol; 2008 Aug; 61(8):958-61. PubMed ID: 18663058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
    Bacher U; Haferlach T; Kern W; Hiddemann W; Schnittger S; Schoch C
    Ann Hematol; 2005 Apr; 84(4):250-7. PubMed ID: 15692838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic analysis in acute myeloid leukaemia.
    Campbell LJ; White JS
    Methods Mol Biol; 2011; 730():63-77. PubMed ID: 21431634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
    Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
    Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.
    Tao J; Zhang X; Lancet J; Bennett JM; Cai L; Papenhausen P; Moscinski L; Zhang L
    Cancer Genet; 2014; 207(10-12):489-94. PubMed ID: 25453399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
    Tefferi A; Levine RL; Kantarjian H
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia.
    Arefi M; Robledo C; Peñarrubia MJ; García de Coca A; Cordero M; Hernández-Rivas JM; García JL
    Eur J Haematol; 2014 Nov; 93(5):422-8. PubMed ID: 24813417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
    Kodali S; Chen C; Rathnasabapathy C; Wang JC
    Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.
    Morris CM
    Methods Mol Biol; 2011; 730():33-61. PubMed ID: 21431633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The myeloid disorders: background.
    Swansbury J
    Methods Mol Biol; 2003; 220():23-42. PubMed ID: 12744204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of growth factor stimulants improves cytogenetic analysis of chronic myeloproliferative disorder patients without alteration to cell lineage or clonality.
    Vaughan BR; Scott MA; Howard JD; Nacheva EP
    Cancer Genet Cytogenet; 2007 Jun; 175(2):98-106. PubMed ID: 17556065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
    Tefferi A; Vardiman JW
    Curr Opin Hematol; 2007 Mar; 14(2):115-22. PubMed ID: 17255788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative disorders.
    Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
    Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
    Bilhou-Nabéra C; Bidet A; Eclache V; Lippert E; Mozziconacci MJ
    Ann Biol Clin (Paris); 2016 Oct; 74(5):517-523. PubMed ID: 27477946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
    Bacher U; Haferlach T; Schoch C
    Cancer Genet Cytogenet; 2005 Jul; 160(2):179-83. PubMed ID: 15993276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.